Company BiomX Inc.

Equities

PHGE

US09090D1037

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nyse Other stock markets 01:40:00 30/04/2024 am IST			5-day change	1st Jan Change
0.3798 ^USD	+8.51%		+28.70%	+35.64%

18/04	Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board	CI
03/04	Transcript : BiomX Inc., Q4 2023 Earnings Call, Apr 03, 2024

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Number of employees: 65

Managers	Title	Age	Since
Jonathan Solomon CEO	Chief Executive Officer	47	28/19/28
Avraham Gabay DFI	Director of Finance/CFO	39	01/11
Anat Primovich IRC	Investor Relations Contact	-	01/21/01
Inbal Benjamini-Elran HRO	Human Resources Officer	-	01/20/01
Myriam Golembo PRN	Corporate Officer/Principal	59	31/19/31
Merav Bassan PRN	Corporate Officer/Principal	59	28/19/28
Assaf Oron PRN	Corporate Officer/Principal	49	28/19/28

Members of the board	Title	Age	Since
Russell Greig CHM	Chairman	71	28/19/28
Jonathan Solomon CEO	Chief Executive Officer	47	28/19/28
Edward Williams BRD	Director/Board Member	68	12/23/12
Alan Moses BRD	Director/Board Member	76	02/20/02

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	55,220,077	38,765,954 ( 70.20 %)	0	70.20 %

Name	Equities	%	Valuation
Deerfield Management Co. LP (Private Equity) 13.27 %	6,110,098	13.27 %	3 M $
Cystic Fibrosis Foundation 9.884 %	4,552,315	9.884 %	2 M $
Nimble Partners LLC 9.879 %	4,550,000	9.879 %	2 M $
OrbiMed Advisors Private Equity 9.809 %	4,517,589	9.809 %	2 M $
AMR Action Fund GP LLC 6.633 %	3,054,870	6.633 %	1 M $
Rodney Hodges 6.166 %	2,839,714	6.166 %	1 M $
Johnson & Johnson Innovation - JJDC, Inc. 4.632 %	2,133,402	4.632 %	960 031 $
Eight Enterprises LLC 2.358 %	1,086,191	2.358 %	488 786 $
Chidozie Ugwumba 2.004 %	922,800	2.004 %	415 260 $
JSR CORPORATION 0.5428 %	250,000	0.5428 %	112 500 $

Name	Equities	%	Valuation
Walleye Capital LLC 0.0276 %	12,688	0.0276 %	4 442 $
Goldman Sachs & Co. LLC 0.0228 %	10,492	0.0228 %	3 673 $
Clear Street LLC 0.003456 %	1,589	0.003456 %	556 $

BiomX, Inc.

22 Einstein Street Floor 4

7414003, Ness Ziona

http://www.biomx.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3798 USD

Average target price

3 USD

Spread / Average Target

+689.89%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOMX INC.	+35.64%	20.97M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B
ARGENX SE	+2.59%	22.18B
BIONTECH SE	-16.67%	21.2B
GENMAB A/S	-9.14%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs